NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Forecast & News

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EGRX stock has increased by 2.7% and is now trading at $40.13. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Eagle Pharmaceuticals.

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Eagle Pharmaceuticals.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) announced its quarterly earnings data on Monday, March, 2nd. The specialty pharmaceutical company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.02. The specialty pharmaceutical company had revenue of $48.30 million for the quarter, compared to the consensus estimate of $49.08 million. Eagle Pharmaceuticals had a return on equity of 9.99% and a net margin of 7.31%. Eagle Pharmaceuticals's revenue was down 13.8% compared to the same quarter last year. During the same period last year, the company posted $1.20 EPS. View Eagle Pharmaceuticals' earnings history.

3 Wall Street analysts have issued 12 month price objectives for Eagle Pharmaceuticals' stock. Their forecasts range from $46.00 to $59.00. On average, they expect Eagle Pharmaceuticals' share price to reach $51.67 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price. View analysts' price targets for Eagle Pharmaceuticals.

News coverage about EGRX stock has trended somewhat negative on Saturday, according to InfoTrie. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eagle Pharmaceuticals earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days. View the latest news aboutEagle Pharmaceuticals.

Eagle Pharmaceuticals saw a increase in short interest in the month of February. As of February 14th, there was short interest totaling 1,870,000 shares, an increase of 8.1% from the January 30th total of 1,730,000 shares. Based on an average daily trading volume, of 143,500 shares, the short-interest ratio is currently 13.0 days. Currently, 14.4% of the shares of the stock are short sold. View Eagle Pharmaceuticals' Current Options Chain.

Some companies that are related to Eagle Pharmaceuticals include Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Eidos Therapeutics (EIDX), Karuna Therapeutics (KRTX), Principia Biopharma (PRNB), Epizyme (EPZM), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Turning Point Therapeutics (TPTX), Insmed (INSM), Arvinas (ARVN), SAGE Therapeutics (SAGE) and Aurinia Pharmaceuticals (AUPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), Celgene (CELG), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), bluebird bio (BLUE), Radius Health (RDUS) and Clovis Oncology (CLVS).

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (13.17%), State Street Corp (4.47%), LSV Asset Management (2.70%), Norges Bank (1.82%), Credit Suisse AG (1.77%) and Chartwell Investment Partners LLC (1.38%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View institutional ownership trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Bank of America Corp DE, FMR LLC, Connor Clark & Lunn Investment Management Ltd., Connor Clark & Lunn Investment Management Ltd., Chicago Equity Partners LLC, Man Group plc, and Oxford Asset Management LLP. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Douglas L Braunstein, Hudson Executive Capital Lp, and Scott Tarriff. View insider buying and selling activity for Eagle Pharmaceuticals.

EGRX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, Goldman Sachs Group Inc., State Street Corp, California Public Employees Retirement System, Schroder Investment Management Group, Janus Henderson Group PLC, and Martingale Asset Management L P. View insider buying and selling activity for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $40.13.

Eagle Pharmaceuticals has a market capitalization of $548.98 million and generates $195.89 million in revenue each year. The specialty pharmaceutical company earns $14.31 million in net income (profit) each year or $1.38 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe. View additional information about Eagle Pharmaceuticals.

The official website for Eagle Pharmaceuticals is http://www.eagleus.com/.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]